AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 15153167
Drug: Azathioprine continued
RxNorm normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Azathioprine continued treatment (dose >1.60 mg/kg/day)
Trial: 15153167
Drug: Azathioprine withdrawal
RxNorm normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Azathioprine withdrawal (dose >1.60 mg/kg/day)
Trial: 11485124
Drug: Sulfasalazine 500
RxNorm normalized name: sulfasalazine 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sulfasalazine 500 mg tablets twice daily
Trial: 7602728
Drug: Vacuum effect
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vacuum effect (change from 40 mL of aspirated air to ≤ 10 mL after 60 mL of air instillation)
Trial: 26714972
Drug: Potassium levels
RxNorm normalized name: Potassium
DrugBank: Potassium (DB14500)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Potassium levels <3.5 mEq/L
Trial: 26714972
Drug: Potassium levels
RxNorm normalized name: Potassium
DrugBank: Potassium (DB14500)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Potassium levels ⩾5 mEq/L
Trial: 26714972
Drug: Potassium levels
RxNorm normalized name: Potassium
DrugBank: Potassium (DB14500)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Potassium levels 3.5 to <4 mEq/L
Trial: 26714972
Drug: Potassium levels
RxNorm normalized name: Potassium
DrugBank: Potassium (DB14500)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Potassium levels ⩾4.5 mEq/L
Trial: 23229850
Drug: Cholestyramine ointment
DrugBank: Cholestyramine (DB01432)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cholestyramine ointment (15%)
Trial: 16645371
Drug: Inhaled Prostacyclin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled Prostacyclin (iPGI2)
Trial: 16645371
Drug: Intravenous vasodilators
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous vasodilators (Control)
Trial: 16645371
Drug: Inhaled drugs
RxNorm normalized name: Inhalation Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled drugs (iNO and iPGI2)
Trial: 12540121
Drug: Acid-etch treatment
RxNorm normalized name: undecylenic acid Topical Solution [Hongo Killer Treatment]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acid-etch treatment
Trial: 8781869
Drug: Caffeine 0
RxNorm normalized name: caffeine 0.65 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine 0 mg.kg‐1 body mass
Trial: 8781869
Drug: Caffeine 5
RxNorm normalized name: caffeine 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine 5 mg.kg‐1 body mass
Trial: 8781869
Drug: Caffeine 9
RxNorm normalized name: multivit,calcium,min/ferrous fum/folic acid/guarana/caffeine 9 mg iron-400 mcg-200 mg ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine 9 mg.kg‐1 body mass
Trial: 1727841
Drug: Nicotinic acid
RxNorm normalized name: Nicotinic acid
DrugBank: Niacin (DB00627)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nicotinic acid (wax-matrix sustained-release niacin, Endur-acin) at doses of 1,000 mg/day, 1,250 mg/day, 1,500 mg/day, or 2,000 mg/day for 8 weeks
Trial: 1727841
Drug: Nicotinic acid
RxNorm normalized name: Nicotinic acid
DrugBank: Niacin (DB00627)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nicotinic acid (wax-matrix sustained-release niacin, Endur-acin) at doses of 1,500 mg and 2,000 mg for older subjects
Trial: 1727841
Drug: Nicotinic acid
RxNorm normalized name: Nicotinic acid
DrugBank: Niacin (DB00627)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nicotinic acid (wax-matrix sustained-release niacin, Endur-acin)
Trial: 6086834
Drug: Comprehensive community
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comprehensive community treatment including a 24-hour crisis service
Trial: 6086834
Drug: Comprehensive community
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comprehensive community treatment
Trial: 26584896
Drug: Pain Recognition
RxNorm normalized name: Dermoplast Pain
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pain Recognition and Treatment (PRT) protocol coupled with basic pain education
Trial: 19761871
Drug: Metformin or
RxNorm normalized name: metformin Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin or Vitamin E
Trial: 9805215
Drug: Low-fat ice
RxNorm normalized name: Hard fat
DrugBank: Hard fat (DB11578)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-fat ice cream (3% fat)
Trial: 9805215
Drug: Standard ice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard ice cream (10% fat)
Trial: 3056240
Drug: Clindamycin (total
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clindamycin (total dose, 2.4 g) plus Amikacin (total dose, 1 g)
Trial: 3056240
Drug: Ticarcillin plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ticarcillin plus Clavulanic acid (total dose, 20.8 g)
Trial: 28911260
Drug: Amiselimod 0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amiselimod 0.1 mg, 0.2 mg, or 0.4 mg
Trial: 28911260
Drug: Amiselimod (various
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amiselimod (various doses)
Trial: 17717914
Drug: Strengthening Pi
RxNorm normalized name: PI-103
DrugBank: PI-103 (DB17046)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Strengthening Pi and activating blood circulation therapy (SPAB)
Trial: 17717914
Drug: Indomethacin and
RxNorm normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Indomethacin and methopterin (Western medicine)
Trial: 17717914
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of SPAB and Western medicine (CM-WM group)
Trial: 15828855
Drug: NuvaRing for
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NuvaRing for 21 days plus amoxicillin on days 1‐10
Trial: 12097784
Drug: Fluoxetine 20
RxNorm normalized name: fluoxetine 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine 20 mg/day reinitiated after relapse from placebo
Trial: 12097784
Drug: Fluoxetine 40
RxNorm normalized name: fluoxetine 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine 40 mg/day (increased from 20 mg/day)
Trial: 12097784
Drug: Fluoxetine 90
RxNorm normalized name: fluoxetine 90 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine 90 mg twice a week (increased from 90 mg weekly)
Trial: 1979763
Drug: Highly purified
RxNorm normalized name: RAYON,PURIFIED
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Highly purified pork insulin (Actrapid)
Trial: 1979763
Drug: Semisynthetic human
RxNorm normalized name: INSULIN,NPH,HUMAN/SEMISYNTHETIC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Semisynthetic human insulin (Actrapid Human)
Trial: 34496
Drug: Triazolam (0.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triazolam (0.6 mg)
Trial: 24434301
Drug: Low doses
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low doses of atorvastatin (10 mg daily) or simvastatin (10-20 mg daily)
Trial: 21890323
Drug: pONS (carbohydrate-containing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: pONS (carbohydrate-containing preconditioning oral nutritional supplement enriched with glutamine, antioxidants, and green tea extract)
Trial: 19598302
Drug: Probiotic combination
RxNorm normalized name: PROBIOTIC COMBINATION CAP/TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotic combination of Lactobacillus acidophilus NCFM and Bifidobacterium lactis Bl‐04
Trial: 17599487
Drug: Aspirin and
RxNorm normalized name: Aspirin and Caffeine Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin and clopidogrel discontinued more than 6 days before surgery (group 1, n = 35)
Trial: 17599487
Drug: Aspirin and
RxNorm normalized name: Aspirin and Caffeine Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin and clopidogrel continued until 3 to 5 days before surgery (group 2, n = 51)
Trial: 17599487
Drug: Aspirin and
RxNorm normalized name: Aspirin and Caffeine Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin and clopidogrel continued within 2 days of surgery (group 3, n = 20)
Trial: 15141801
Drug: Remifentanil 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil 0.5 microg kg(‐1) i.v. with propofol 2 mg kg(‐1) i.v. and 60% nitrous oxide in oxygen
Trial: 15141801
Drug: Remifentanil 1
RxNorm normalized name: remifentanil 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil 1 microg kg(‐1) i.v. with propofol 2 mg kg(‐1) i.v. and 60% nitrous oxide in oxygen
Trial: 15141801
Drug: Remifentanil 1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil 1.5 microg kg(‐1) i.v. with propofol 2 mg kg(‐1) i.v. and 60% nitrous oxide in oxygen
Trial: 11841525
Drug: Intervention arm
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intervention arm of a trial of the effectiveness of depression treatment
Trial: 9823729
Drug: All gel
RxNorm normalized name: ALCOHOL 65 mL in 100 mL TOPICAL GEL [Clean All Gel Hand Sanitizer]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All gel formulations
Trial: 7714603
Drug: 0.6 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.6 mg/kg tirilazad per day intravenously
Trial: 7714603
Drug: 2 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg/kg tirilazad per day intravenously
Trial: 7714603
Drug: 6 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 mg/kg tirilazad per day intravenously
Trial: 2468745
Drug: Mitoxantrone (14
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mitoxantrone (14 mg/m2 IV every 3 weeks)
Trial: 2468745
Drug: Doxorubicin (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxorubicin (75 mg/m2 IV every 3 weeks)
Trial: 28105513
Drug: Ginkgo terpene
RxNorm normalized name: terpene resin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ginkgo terpene lactones meglumine injection (GMI)
Trial: 26421861
Drug: Cognitive-Behavioral Prevention
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-Behavioral Prevention (CBP) program consisting of 8 weekly 90-minute group sessions followed by 6 monthly continuation sessions.
Trial: 15285777
Drug: Levodopa (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levodopa (200 mg as Sinemet)
Trial: 11103753
Drug: Angiotensin II
RxNorm normalized name: Angiotensin II
DrugBank: Angiotensin II (DB11842)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Angiotensin II infusion for 6 hours
Trial: 11103753
Drug: Angiotensin II
RxNorm normalized name: Angiotensin II
DrugBank: Angiotensin II (DB11842)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Angiotensin II infusion with valsartan pretreatment
Trial: 1449046
Drug: Acipimox (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acipimox (250 mg x 3) for three months
Trial: 1449046
Drug: Acipimox (after
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acipimox (after three months treatment)
Trial: 1449046
Drug: Acipimox (before
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acipimox (before treatment)
Trial: 16834838
Drug: Tramadol ER
RxNorm normalized name: tramadol Extended Release Oral Capsule
DrugBank: Tramadol (DB00193)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Tramadol ER 100 mg once daily
Trial: 16834838
Drug: Tramadol ER
RxNorm normalized name: tramadol Extended Release Oral Capsule
DrugBank: Tramadol (DB00193)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Tramadol ER 200 mg once daily
Trial: 16834838
Drug: Tramadol ER
RxNorm normalized name: tramadol Extended Release Oral Capsule
DrugBank: Tramadol (DB00193)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Tramadol ER 300 mg once daily
Trial: 16834838
Drug: Tramadol ER
RxNorm normalized name: tramadol Extended Release Oral Capsule
DrugBank: Tramadol (DB00193)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Tramadol ER 400 mg once daily
Trial: 12768357
Drug: Combination treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination treatment of 100 mg regular-release (rr) and 100 mg sustained-release (sr) L-dopa/benserazide
Trial: 12768357
Drug: Combination treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination treatment of 100 mg regular-release (rr) and 100 mg sustained-release (sr) L-dopa/benserazide after 4 weeks
Trial: 10671905
Drug: Milnacipran 12.5
RxNorm normalized name: milnacipran 12.5 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Milnacipran 12.5 mg, 25 mg, 50 mg, 100 mg (single dose)
Trial: 10671905
Drug: Milnacipran 75
RxNorm normalized name: MILNACIPRAN
DrugBank: Milnacipran (DB04896)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Milnacipran 75 mg (50 mg + 25 mg) per day
Trial: 10671905
Drug: Amitriptyline 50
RxNorm normalized name: amitriptyline 50 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amitriptyline 50 mg (25 mg + 25 mg) per day
Trial: 9176040
Drug: Urodilatin infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Urodilatin infusion (20 ng min‐1 kg‐1)
Trial: 9176040
Drug: Urodilatin infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Urodilatin infusion (40 ng min‐1 kg‐1)
Trial: 8260563
Drug: Methylphenidate (optimal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylphenidate (optimal drug dosage)
Trial: 3910338
Drug: 0.2% NaF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2% NaF solution rinse every fortnight
Trial: 22012149
Drug: Weekly Monitoring
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Weekly Monitoring Control
Trial: 1685166
Drug: Shortwave diathermy
RxNorm normalized name: glucose
DrugBank: Dextrose, unspecified form (DB09341)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Shortwave diathermy and exercise therapy
Trial: 7139526
Drug: Local radiation
RxNorm normalized name: docusate calcium / phenolphthalein Oral Capsule [Docal]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local radiation with or without chemotherapy
Trial: 28944412
Drug: Split-dose regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Split-dose regimen (all solutions)
Trial: 28944412
Drug: Single-dose regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-dose regimen (all solutions)
Trial: 21111555
Drug: Adjusted-dose warfarin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjusted-dose warfarin (target INR 2 to 3)
Trial: 21111555
Drug: Fixed-dose ximelagatran
RxNorm normalized name: Humalog Mix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed-dose ximelagatran 36 mg twice daily
Trial: 17288690
Drug: Erythropoietic protein
RxNorm normalized name: protein C
DrugBank: Protein C (DB11312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erythropoietic protein therapy
Trial: 15044883
Drug: Simethicone (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simethicone (80 mg)
Trial: 15044883
Drug: No supplemental
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No supplemental medication
Trial: 3243093
Drug: Cefaclor thrice
RxNorm normalized name: Cefaclor
DrugBank: Cefaclor (DB00833)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cefaclor thrice daily
Trial: 24169612
Drug: Bardoxolone methyl
RxNorm normalized name: Bardoxolone methyl
DrugBank: Bardoxolone methyl (DB05983)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bardoxolone methyl added to guideline-recommended treatment including inhibitors of the renin-angiotensin-aldosterone system
Trial: 21159499
Drug: Tiotropium (18
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tiotropium (18 μg) after 30 days
Trial: 17077374
Drug: Usual and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual and customary care (n = 116; ranging from no treatment after concluding formal rehabilitation to pharmacologic or physiotherapeutic interventions)
Trial: 12798886
Drug: Goserelin (3.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Goserelin (3.6 mg, s.c. injection)
Trial: 12798886
Drug: Fulvestrant (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fulvestrant (50 mg, 125 mg, or 250 mg, i.m. injection)
Trial: 3875451
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg pirazolac 3-times daily for 7 days
Trial: 3875451
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg diclofenac sodium 3-times daily for 7 days
Trial: 28940213
Drug: Habit reversal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Habit reversal treatment (HR) + mometasone furoate (potent steroid)
Trial: 28940213
Drug: Mometasone furoate
RxNorm normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Mometasone furoate (potent steroid) alone
Trial: 24071762
Drug: Pentaerithrityl tetranitrate
RxNorm normalized name: Pentaerithrityl tetranitrate
DrugBank: Pentaerythritol tetranitrate (DB06154)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pentaerithrityl tetranitrate (PETN) 80 mg b.i.d.
Trial: 20064822
Drug: RAAS inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RAAS inhibitors (Group 2)
Trial: 20064822
Drug: RAAS inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RAAS inhibitors vs Control
Trial: 19018483
Drug: Terlipressin in
RxNorm normalized name: terlipressin Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Terlipressin in combination with albumin
Trial: 12552210
Drug: Intrathecal morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrathecal morphine + 1 microg neostigmine
Trial: 12552210
Drug: Intrathecal morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrathecal morphine + 2.5 microg neostigmine
Trial: 12552210
Drug: Intrathecal morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrathecal morphine + 5 microg neostigmine
Trial: 8681637
Drug: LPS (lipopolysaccharide)
RxNorm normalized name: LP-20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LPS (lipopolysaccharide) inhalation
Trial: 8681637
Drug: CDE (corn
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CDE (corn dust extract) inhalation
Trial: 1869725
Drug: 1 g
RxNorm normalized name: Molds 1 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 g of methylprednisolone
Trial: 6857251
Drug: Control animals
RxNorm normalized name: animals
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control animals (dissociated drug histories)
Trial: 27014997
Drug: Secukinumab (IV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Secukinumab (IV 10 mg/kg at weeks 0, 2, 4 followed by subcutaneous 150 mg or 75 mg)
Trial: 27014997
Drug: Secukinumab (IV→150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Secukinumab (IV→150 mg)
Trial: 27014997
Drug: Secukinumab (IV→75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Secukinumab (IV→75 mg)
Trial: 18629732
Drug: Smoking cessation
RxNorm normalized name: Zyban 150 MG Smoking Cessation 12 HR Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Smoking cessation intervention consisting of education and psychological support, with or without pharmacological therapy, associated with follow-up phone calls
Trial: 15870599
Drug: Masking in
RxNorm normalized name: MASK
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Masking in medical treatments
Trial: 1091665
Drug: Previous medication
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Previous medication
Trial: 22648444
Drug: Active low-level
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active low-level light therapy (LLLT)
Trial: 12739312
Drug: Triptans (acute
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triptans (acute migraine pharmacotherapy)
Trial: 12739312
Drug: Preventive therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preventive therapy
Trial: 8281563
Drug: Low-fluoride solution
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-fluoride solution (0.5% F) applied 10 times a year
Trial: 8281563
Drug: Standard topical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard topical amine fluoride solution (1% F)
Trial: 26499921
Drug: E10030 (0.03
FDA approved: no
EMA approved: no
PMDA approved: no
Description: E10030 (0.03 mg) in combination with ranibizumab (0.5 mg)
Trial: 26499921
Drug: E10030 (0.3,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: E10030 (0.3, 1.5, or 3.0 mg) in combination with ranibizumab (0.5 mg)
Trial: 22900702
Drug: Chlorogenic acid
RxNorm normalized name: chlorogenic acid
DrugBank: Chlorogenic Acid (DB12029)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlorogenic acid (400 mg, equivalent to 2 cups of coffee)
Trial: 17064525
Drug: Yunnan Baiyao
RxNorm normalized name: CAMPHOR (SYNTHETIC) 40.74 mg / MENTHOL 51.84 mg / METHYL SALICYLATE 117.998 mg TOPICAL PATCH [Yunnan Baiyao Pain Relieving]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yunnan Baiyao 500 mg three times daily for 5 days
Trial: 3799505
Drug: 1000 mg
RxNorm normalized name: bran 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000 mg of elemental calcium for 8 weeks
Trial: 29426006
Drug: Ayurvedic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ayurvedic treatment (multi-modal)
Trial: 17765316
Drug: p38-MAPK inhibitors
RxNorm normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: p38-MAPK inhibitors
Trial: 12052577
Drug: Injectable diacetylmorphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injectable diacetylmorphine (pharmaceutical heroin)
Trial: 12052577
Drug: Intravenous (IV)
RxNorm normalized name: intravenous (IV) infusion pump
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous (IV) application of heroin under medical supervision